StemCell Therapy

In a analysts note revealed to clients and investors on Friday, 29 November, equity research analysts at BidaskScores research division upgraded Gamida Cell (NASDAQ:GMDA)s stock to a Hold.

Axt Inc (NASDAQ:AXTI) had a decrease of 0.34% in short interest. AXTIs SI was 1.63M shares in December as released by FINRA. Its down 0.34% from 1.64M shares previously. With 349,800 avg volume, 5 days are for Axt Inc (NASDAQ:AXTI)s short sellers to cover AXTIs short positions. The SI to Axt Incs float is 4.63%. It closed at $3.16 lastly. It is up 43.44% since December 2, 2018 and is downtrending. It has underperformed by 43.44% the S&P500. Some Historical AXTI News: 14/05/2018 Eam Investors LLC Exits Position in AXT; 25/04/2018 AXT 1Q EPS 7c; 24/04/2018 AXT Short-Interest Ratio Rises 33% to 7 Days; 21/04/2018 DJ AXT Inc, Inst Holders, 1Q 2018 (AXTI); 11/04/2018 AXT: Demand Remains Soli; 14/03/2018 AXT Closes Below 200-Day Moving Average: Technicals; 24/05/2018 AXT Short-Interest Ratio Rises 63% to 10 Days; 11/04/2018 AXT INC COMPLETED FIRST PHASE OF FACILITIZATION OF ITS NEW MANUFACTURING FACILITY IN DINGXING, CHINA; 11/04/2018 AXT Inc. Lowers 1Q Guidance; 11/04/2018 AXT Completes First Phase of New Factory in Dingxing, China

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company has market cap of $182.65 million. The company's lead product candidate is NiCord, a nicotinamide -expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It currently has negative earnings. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma.

Analysts await Gamida Cell Ltd. (NASDAQ:GMDA) to report earnings on February, 24. After $-0.30 actual earnings per share reported by Gamida Cell Ltd. for the previous quarter, Wall Street now forecasts 30.00% negative EPS growth.

The stock increased 5.96% or $0.31 during the last trading session, reaching $5.43. About 92,358 shares traded or 204.50% up from the average. Gamida Cell Ltd. (NASDAQ:GMDA) has 0.00% since December 2, 2018 and is . It has by 0.00% the S&P500.

More notable recent Gamida Cell Ltd. (NASDAQ:GMDA) news were published by: Finance.Yahoo.com which released: Will Gamida Cell (NASDAQ:GMDA) Spend Its Cash Wisely? Yahoo Finance on November 19, 2019, also Seekingalpha.com with their article: Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q3 2019 Results Earnings Call Transcript Seeking Alpha published on November 13, 2019, Businesswire.com published: Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast Business Wire on November 05, 2019. More interesting news about Gamida Cell Ltd. (NASDAQ:GMDA) were released by: Businesswire.com and their article: Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference Business Wire published on November 21, 2019 as well as Businesswire.coms news article titled: Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting Business Wire with publication date: November 06, 2019.

AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. The company has market cap of $127.10 million. The firm makes its semiconductor substrates using its proprietary vertical gradient freeze technology. It currently has negative earnings. It offers semi-insulating gallium with arsenic substrates, which are used for applications in power amplifiers for wireless devices, and transistors and solar cells for drones.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
BidaskScore Ups Gamida Cell (GMDA); Shorts at Axt (AXTI) Lowered By 0.34% - The Broch Herald

This entry was posted on December 3, 2019 at 6:45 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |